“Merck and Schering-Plough must pay $688 million for lying to shareholders about the benefits of cholesterol drug Vytorin over its cheaper, generic version”

$688 Million Settlement Approved in Merck Case By ROSE BOUBOUSHIAN (CN) – Merck and Schering-Plough must pay $688 million for lying to shareholders about the benefits of cholesterol drug Vytorin over its cheaper, generic version, a federal judge ruled. The complaint, filed in New Jersey federal court in 2008, accused Merck & Co. Inc. fka…

Statins block the ability of exercise to improve fitness levels

Cholesterol-Lowering Drug May Reduce Exercise Benefits for Obese Adults, MU Study Finds May 15, 2013 Story Contact(s): Jesslyn  Chew, ChewJ@missouri.edu, (573) 882-8353 By Kate McIntyre COLUMBIA, Mo. – Statins, the most widely prescribed drugs worldwide, are often suggested to lower cholesterol and prevent heart disease in individuals with obesity, diabetes and metabolic syndrome, which is…

Long-term effects of statin therapy could lead to transient or permanent cognitive impairment

2009 study posted for filing Contact: Nick Zagorski nzagorski@asbmb.org 301-634-7366 American Society for Biochemistry and Molecular Biology Statins show dramatic drug and cell dependent effects in the brain Besides their tremendous value in treating high cholesterol and lowering the risk of heart disease, statins have also been reported to potentially lower the risks of other…

Cholesterol-lowering drug linked to sleep disruptions – Possibly promoting weight gain and insulin resistance

Cholesterol-lowering drug linked to sleep disruptions   ORLANDO, Nov. 7 — A cholesterol-lowering drug appears to disrupt sleep patterns of some patients, researchers reported at the American Heart Association’s Scientific Sessions 2007.   “The findings are significant because sleep problems can affect quality of life and may have adverse health consequences, such as promoting weight…